Rubicon Research
NSE: RUBICON · ISIN INE506V01022 · Healthcare
₹1,737.50+6.70 (+0.39%)
Monday 9 November, 12:57 IST. Delayed. Source: Yahoo Finance.
Price chart
₹1,737.50 +6.70 (+0.39%) today
The day
- Previous close
- ₹1,730.80
- Open
- ₹1,731.00
- Day high
- ₹1,742.70
- Day low
- ₹1,653.40
Listed on NSE since 16 October 2025.
Key numbers
- Market value
- ₹27,468 Cr
- P/E (trailing)
- 95.58
- EPS (trailing)
- ₹17.36
- Price to book
- 19.38
- Dividend yield
- 0.09%
- Return on equity
- 31.3%
- Debt to equity
- 0.35
- Profit margin
- 15.5%
- Volume today
- 1.30 L
- Average volume
- 3.20 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY25 | ₹1,267.10 Cr | – |
| FY26 | ₹1,731.17 Cr | ₹246.74 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹576 Cr | ₹90 Cr | +68.0% |
| Q1 FY27Apr–Jun 2026 | ₹534 Cr | ₹85 Cr | – |
| Q4 FY26Jan–Mar 2026Audited | ₹514 Cr | ₹77 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹476 Cr | ₹73 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹412 Cr | ₹54 Cr | – |
Source: Rubicon Research’s results filed with NSE, consolidated (the whole group). Net profit is the share of Rubicon Research’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹616 Cr | ₹508 Cr |
| Investments | ₹29 Cr | ₹27 Cr |
| Inventories | ₹790 Cr | ₹729 Cr |
| Owed by customers | ₹578 Cr | ₹509 Cr |
| Cash and equivalents | ₹209 Cr | ₹186 Cr |
| Total assets | ₹2,761 Cr | ₹2,327 Cr |
| Borrowings | ₹398 Cr | ₹259 Cr |
| Total liabilities | ₹1,330 Cr | ₹1,038 Cr |
| Shareholders’ equity | ₹1,416 Cr | ₹1,289 Cr |
Source: Rubicon Research’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Rubicon Research
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.
- Industry
- Drug Manufacturers - General
- Based in
- Mumbai
- Employees
- 1,290
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Rubicon Research in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 1.50 Per Share
Dividend · ex-date 7 August 2026
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.